Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03734653 · ClinicalTrials.gov registry record · Early Phase 1
Testosterone Therapy in Castration Resistant Prostate Cancer
A Early Phase 1 study of Prostate Cancer and Castration-resistant Prostate Cancer, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03734653 is a Early Phase 1 study of Prostate Cancer and Castration-resistant Prostate Cancer that has completed, run by University of Colorado, Denver. The registered enrollment target is 30 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03734653, a Early Phase 1 study of Prostate Cancer and Castration-resistant Prostate Cancer, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-labeled, single-arm, interventional pilot study. It is being done to determine the feasibility of the administration of transdermal testosterone alternating with enzalutamide, as well as the safety and efficacy.
Conditions Studied
Interventions
- DRUG Transdermal Testosterone
- DRUG Standard of Care, Enzalutamide
Study Locations (1)
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-01-18 |
| Est. Completion | 2025-09-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03734653
The ClinicalTrials.gov registry entry for NCT03734653 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Transdermal Testosterone is the first listed.
NCT03734653 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03734653 about?
NCT03734653 is a clinical study titled "Testosterone Therapy in Castration Resistant Prostate Cancer". This is an open-labeled, single-arm, interventional pilot study. It is being done to determine the feasibility of the administration of transdermal testosterone alternating with enzalutamide, as well as the safety and efficacy.
What is the current status of trial NCT03734653?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2019-01-18. Estimated completion is 2025-09-30.
What conditions does trial NCT03734653 study?
This clinical trial studies the following conditions: Prostate Cancer, Castration-resistant Prostate Cancer.
What interventions are being tested in trial NCT03734653?
The interventions under investigation include: Transdermal Testosterone (DRUG), Standard of Care, Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT03734653?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03734653 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
RECRUITING · Early Phase 1
-
Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
RECRUITING · Early Phase 1
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RECRUITING · Early Phase 1
-
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
RECRUITING · Early Phase 1
-
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
RECRUITING · Early Phase 1
-
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.